The high-resolution three-dimensional magnetic detector system 3D-MAGMA accurately measures gastric and small bowel motility in people with type 2 diabetes with neuropathy

Not Applicable

Completed

• Conditions: People with type 2 diabetes using insulin and peripheral neuropathy; Nutritional, Metabolic, Endocrine; Type 2 diabetes

• Registration Number: ISRCTN81917128
• Lead Sponsor: niversity Hospital Jena

Brief Summary

2020 results in https://pubmed.ncbi.nlm.nih.gov/32557505/ (added 01/07/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-15
• Study Completion: 2019-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

1. Age 18-85 years
2. NSS >4/10 and NDS >6/10
3. Blood glucose 4-12 mmol/l before testing
4. Written informed consent

Exclusion Criteria

1. Surgery of stomach or small bowel
2. Opioids, erythromycin, prokinetic agents, L-dopa, ß-agonists, benzodiazepines, ondansetron, tricyclic antidepressives, atropine
3. Eating disorder, portal hypertension, gastric cancer, systemic sclerosis, myotonic dystrophy
4. Pregnancy
5. Implanted cardiac pacemaker/defibrillator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Residence time (min) of the capsule in the stomach measured by 3D-MAGMA

Secondary Outcome Measures

Name	Time	Method
<br> 1. Residence time (min) of the capsule in the duodenum measured by 3D-MAGMA<br> 2. Residence time (min) of the capsule in the first 50 cm of the jejunum measured by 3D-MAGMA<br>